A groundbreaking fluorescent reporter enabling real-time visualization of biologically active iron and oxygen at the single-cell level inside living organisms has been developed by researchers at the Institute of Science Tokyo. This revolutionary tool, named LiON (labile iron and oxygen notifier), ushers in a new era for cellular biology by offering unprecedented insight into the dynamic interplay and distribution of these essential elements within living tissues. Published in the esteemed journal Cell Reports Methods, this innovation promises to transform the study of fundamental physiological processes and complex diseases, from oncology and liver pathology to neurodegenerative disorders and aging.

Iron and oxygen are indispensable to cellular function, acting as core contributors to energy production, metabolic regulation, and DNA synthesis. Despite their vital roles, maintaining the delicate balance and spatial distribution of labile ferrous iron and reactive oxygen species remains critical, as disruptions often lead to cellular damage and disease. Historically, the challenge has been the absence of imaging tools capable of monitoring these elements within living cells at sufficient resolution, particularly differentiating biologically active forms from inert reservoirs.

Traditional methods of detecting iron, such as histochemical staining or mass spectrometry, require fixed tissue samples, offering only static snapshots devoid of temporal context. Although advanced clinical imaging modalities like magnetic resonance imaging enable in vivo iron mapping, they lack cellular resolution and fail to discriminate between active and stored iron pools. This limitation impairs the ability to study cellular heterogeneity and microenvironmental influences critical to disease pathogenesis.

To bridge this gap, the team led by Professor Toshiro Moroishi and doctoral researcher Ayato Maeda ingeniously exploited the iron- and oxygen-sensitive regulatory domain of FBXL5, a protein known to undergo degradation in low-iron and low-oxygen conditions. By genetically fusing this domain to a red fluorescent protein while coupling it with a stable green fluorescent protein, they engineered a ratiometric biosensor. Variations in red-to-green fluorescence ratios directly reflect intracellular labile iron and oxygen levels, enabling precise, quantitative assessments at single-cell resolution in living tissues.

Generating transgenic mice expressing LiON, the investigators revealed remarkable gradients and heterogeneity in iron and oxygen distribution across various organs and within homogeneous cell populations. For instance, they identified spatially distinct iron accumulation proximal to portal veins in the liver, highlighting areas susceptible to oxidative stress and metabolic dysfunction. These nuanced observations suggest complex regulatory mechanisms governing iron homeostasis that could not previously be elucidated in vivo.

Beyond fundamental biology, the capacity to monitor labile iron and oxygen in living systems has profound clinical implications. Iron dysregulation and hypoxia are hallmarks of cancer progression, neurodegeneration, and age-related tissue decline. The ability to dynamically track these parameters within specific cell types allows for the investigation of pathophysiological processes at an unprecedented scale, facilitating the development and evaluation of targeted therapies.

Importantly, the modular genetic design of LiON enables conditional activation in defined tissues or cell populations using well-established genetic tools. This versatility empowers researchers to tailor investigations according to disease models or biological questions, drastically expanding the utility of this fluorescent reporter across scientific disciplines. It also paves the way for high-throughput screening approaches and longitudinal studies previously unattainable.

Technically, the LiON sensor leverages competitive degradation pathways mediated by FBXL5’s hemerythrin-like domain, which senses iron and oxygen availability to regulate protein stability. When iron and oxygen are sufficient, FBXL5 remains stable, maintaining the red fluorescence. Under conditions of deficiency, FBXL5 is degraded, reducing red fluorescence and shifting the fluorescence ratio. By normalizing against stable green fluorescence, this ratiometric approach cancels out confounding factors such as expression levels or photobleaching, ensuring robust quantification.

Further development of LiON may enable integration with multiphoton or super-resolution microscopy, amplifying the ability to investigate cellular metabolism and microenvironmental niches in unprecedented detail. Moreover, its application in live imaging models can accelerate translational research by offering real-time insights into therapeutic interventions and disease progression, a vital step toward precision medicine.

The researchers emphasize that understanding heterogeneity in iron and oxygen management at the single-cell level will clarify diverse cellular responses within tissues, facilitating the identification of vulnerable or resistant cell populations. This information is invaluable for unraveling mechanisms underpinning complex diseases, optimizing drug delivery, and minimizing off-target effects.

As the first fluorescent reporter capable of in vivo, single-cell resolution imaging of labile iron and oxygen, LiON represents a transformative leap forward. The integration of this tool into mainstream biomedical research has the potential to catalyze breakthroughs spanning from fundamental cell biology to clinical therapeutics, establishing a new paradigm in the visualization and understanding of elemental biology.

In the words of Professor Moroishi, “LiON opens a window into cellular microenvironments that were previously invisible, enabling us to observe and quantify critical biochemical landscapes that dictate health and disease. We anticipate that this technology will become an indispensable asset across many branches of life science research.”

With the establishment of the Institute of Science Tokyo, a visionary new institution formed through the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, this breakthrough exemplifies a commitment to pioneering innovative science aimed at enhancing human well-being. The convergence of multidisciplinary expertise and cutting-edge technology exemplified by LiON underscores the promise of collaborative research to address some of the most pressing biomedical challenges of our time.

Subject of Research: Animals
Article Title: In vivo visualization of bioactive iron and oxygen using LiON, the labile iron and oxygen notifier
News Publication Date: 8-May-2026
Web References: DOI: 10.1016/j.crmeth.2026.101431
Image Credits: Institute of Science Tokyo
Keywords: Life sciences, Cell biology, Fluorescent proteins, Biomolecules, Biochemistry, Iron, Oxygen, Human health, Diseases and disorders, Neurodegenerative diseases, Cancer research, Clinical medicine

In the ongoing battle against prostate cancer, researchers have uncovered a biochemical pathway that promises to revolutionize treatment strategies. A recent study by Zhang, H., Feng, T., Lv, M., and colleagues, published in Cell Death Discovery, reveals how quinolinic acid, a metabolite derived from the enzyme HAAO, significantly influences androgen receptor (AR) signaling via an FDPS-dependent mechanism. This discovery not only deepens our understanding of prostate cancer biology but also highlights a novel avenue for enhancing the efficacy of combination therapies.

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, with androgen receptor signaling playing a pivotal role in disease progression and therapy resistance. Androgen deprivation therapies (ADT) have long been the frontline treatment; however, many patients eventually develop castration-resistant prostate cancer (CRPC), underscoring the urgent need for new molecular targets and therapeutic strategies. The study conducted by Zhang and colleagues brings to light the critical interplay between metabolites in the kynurenine pathway and AR signaling, potentially offering new hope for overcoming therapeutic resistance.

Central to their findings is quinolinic acid (QA), a metabolite produced downstream of 3-hydroxyanthranilic acid oxygenase (HAAO) activity within the kynurenine pathway of tryptophan metabolism. Quinolinic acid has traditionally been studied for its neurotoxic properties, but this research innovatively identifies QA as a key modulator within prostate cancer cells. The team demonstrated that HAAO expression is markedly elevated in prostate cancer tissues, correlating with advanced disease stages and poorer prognosis.

Mechanistically, quinolinic acid appears to fuel FDPS (farnesyl diphosphate synthase)-dependent androgen receptor signaling. FDPS is a crucial enzyme in the mevalonate pathway, responsible for the synthesis of isoprenoids, which are vital for protein prenylation and cellular proliferation. The researchers showed that elevated QA enhances FDPS activity, leading to increased AR signaling activity. This hyperactivation of AR signaling amplifies cancer cell growth and survival, facilitating resistance to standard therapies.

What makes this discovery particularly compelling is the demonstration that modulating levels of quinolinic acid can sensitize prostate cancer cells to combination therapeutic approaches. The study revealed that inhibiting HAAO or reducing quinolinic acid production diminishes FDPS-dependent AR signaling, thereby suppressing tumor cell proliferation and improving the effectiveness of anti-androgen drugs. These findings suggest a promising therapeutic window where targeting metabolic pathways can synergize with hormonal therapies to overcome resistance.

The implications of these results extend beyond a simple metabolic snapshot. They connect two major biological systems—the kynurenine pathway and the mevalonate pathway—each with independent significance in cancer biology but now linked through quinolinic acid’s regulatory effects. This metabolic crosstalk introduces a paradigm shift in how metabolic intermediates can be exploited to influence oncogenic signaling cascades.

Moreover, the study utilized a combination of advanced molecular techniques including transcriptomics, metabolomics, and functional assays in both in vitro and in vivo models. These comprehensive approaches validated the critical role of HAAO-derived quinolinic acid and its impact on FDPS expression and activity. Importantly, patient-derived xenografts and clinical data underscored the translational relevance of the findings, suggesting readiness for clinical exploration.

Therapeutically, the prospect of combining HAAO inhibitors or agents targeting quinolinic acid synthesis with established anti-androgen therapies such as enzalutamide marks a significant advancement. This combination strategy could potentially prevent or delay the onset of treatment resistance, a major hurdle in managing advanced prostate cancer. Additionally, the study hints at the broader possibility of targeting metabolic vulnerabilities in other androgen-driven cancers.

From a mechanistic perspective, the identification of quinolinic acid as an oncometabolite challenges previous notions relegating it to neurotoxicity roles. It invites further exploration of how metabolic byproducts can act as signaling molecules within the tumor microenvironment, influencing cancer cell behavior and treatment outcomes. This insight opens doors for novel biomarkers that can predict response to therapy and guide personalized medicine approaches.

Furthermore, the study paves the way to investigate whether similar metabolic dependencies exist in other malignancies where steroid hormone receptor signaling is critical. If so, the HAAO-FDPS-AR axis may become a universal target across multiple cancer types, broadening the scope of therapeutic interventions beyond prostate cancer alone.

On the molecular signaling axis, the team discovered that quinolinic acid’s impact on FDPS promotes AR nuclear translocation and transcriptional activity, leading to enhanced expression of AR target genes that drive proliferation and survival pathways. This detailed mechanistic insight provides concrete targets for pharmacological intervention and biomarker development.

This groundbreaking study also raises important questions about the metabolic plasticity of cancer cells and their ability to adapt biosynthetic pathways to sustain oncogenic signaling. Understanding how cancer cells leverage metabolites like quinolinic acid could illuminate resistance mechanisms and identify vulnerabilities exploitable by combination therapies.

In conclusion, the elucidation of HAAO-derived quinolinic acid as a central actor fueling FDPS-dependent androgen receptor signaling heralds a novel metabolic axis driving prostate cancer progression and therapy resistance. By bridging metabolic biochemistry and signal transduction, the research sets the stage for innovative treatment paradigms that combine metabolic inhibition with hormonal therapy, potentially transforming patient outcomes in prostate cancer and beyond.

Zhang and colleagues’ work exemplifies the power of integrative omics and translational research in unraveling complex cancer biology, inviting the scientific community to rethink how metabolic intermediates can be harnessed in the fight against malignancy. As research advances, the HAAO-quinolinic acid-FDPS-AR signaling axis may well become a cornerstone in precision oncology strategies targeting prostate cancer metabolism and hormone receptor signaling.

Subject of Research: Prostate cancer metabolism and androgen receptor signaling modulation by HAAO-derived quinolinic acid.

Article Title: HAAO-derived quinolinic acid fuels FDPS-dependent AR signaling and sensitizes prostate cancer to combination therapy.

Article References:
Zhang, H., Feng, T., Lv, M. et al. HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03203-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03203-x